General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

NPA and Age UK ask for help on building polypharmacy dossier

NPA and Age UK ask for help on building polypharmacy dossier

July 25 2018 The National Pharmacy Association is asking its members for case studies on...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

NHS Digital seeks views on SCR with Additional Information

NHS Digital seeks views on SCR with Additional Information

July 24 2018 A survey to assess the benefits and/or disadvantages of health professionals...

  • General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    Tuesday, 31 July 2018 15:31
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:08
  • NPA and Age UK ask for help on building polypharmacy dossier

    NPA and Age UK ask for help on building polypharmacy dossier

    Wednesday, 25 July 2018 13:46
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 12:53
  • NHS Digital seeks views on SCR with Additional Information

    NHS Digital seeks views on SCR with Additional Information

    Tuesday, 24 July 2018 12:41

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

pills1577x362April 13 2016

The Scottish Medicines Consortium and the All Wales Medicines Strategy Group have announced their latest recommendations for NHS usage of medicines.

SMC has approved three new medicines for routine use by NHS Scotland:

  • everolimus (Afinitor) for advanced breast cancer
  • isavuconazole (Cresemba) for invasive aspergillosis and mucormycosis (serious fungal infections)
  • Camellia sinensis (Catephen) in an ointment for genital and perianal warts.

The committee recommended against NHS use of ataluren (Translarna) for use in Duchenne muscular dystrophy and eculizumab for paroxysmal nocturnal haemoglobinuria (PNH). In both cases, SMC said there was too much uncertainty about overall benefits in relation to cost.

In Wales, the AWMSG’s April recommendations are:

  • oseltamivir (Tamiflu) for infants less than one year old including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community
  • sorafenib (Nexavar) for restricted use treating hepatocellular carcinoma
  • ulipristal acetate (Esmya) for intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age
  • prucalopride (Resolor) for treating chronic constipation in men in whom laxatives fail to provide adequate relief
  • ivermectin (Soolantra) for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adults
  • ustekinumab (Stelara) for treating chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Links:

SMC announcement

AWMSG announcement

Practice News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...